Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.